期刊文献+

姜黄素CTPP-PEG-PCL胶束的制备及体外评价 被引量:8

Preparation and in vitro evaluation of curcumin CTPP-PEG-PCL micelles
原文传递
导出
摘要 该研究合成了材料3-羧丙基-三苯基溴化鏻-聚乙二醇-聚己内酯(CTPP-PEG-PCL),并且采用自组装溶剂挥发法制备载姜黄素CTPP-PEG-PCL胶束,芘荧光光谱法测定临界胶束浓度(critical micelle concentration,CMC),考察粒径、包封率、形态、体外释放度;采用MTT实验进行肝星状细胞毒性评价。所得材料CTPP-PEG-PCL经1H NMR表征确证其结构,CMC为2.252 mg.L-1,胶束粒径约为190 nm,含药量为(0.66±0.008)g.L-1,包封率(94±0.6)%,体外释放显示缓释特性,姜黄素胶束对肝星状细胞的生长抑制率显著高于姜黄素原料药(P<0.05)。表明CTPP-PEG-PCL胶束临界胶束浓度小,包封率高,肝星状细胞生长抑制效果显著。 To synthetize 3-carboxypropyl-triphenylphosponium bromide-polycaprolacton-CTPP-PEG-PC, and prepare curcumin CTPP-PEG-PCL mieelles by using the self-assembled emulsion solvent evaporation method, in order to determine the critical micelle concentration (CMC) with the pyrene fluorescent probe technology, detect the particle size, entrapment efficiency (%), morpheme and in vitro release rate, and evaluate the cytotoxicity of hepatic stellate cells with MTY assay. The structure of CTPP-PEG-PCL had been identified by IH-NMR spectra. Specifically, the CMC of polymer was 2. 25 mg . L-l , the average size was 190 nm, the drug con- tent was (0. 66±0. 008) g . L -1, and the entrapment efficiency was (94 ±0. 6) %. The in vitro release results showed ettrcumin micelles had a significant higher inhibition ratio in the growth of hepatic stellate cells than crude ettreumin (P 〈 0. 05 ). This suggested that CTPP-PEG- PCL mieelles feature low CMC, high encapsulation efficiency and notable inhibition effect in growth of hepatic stellate cells.
出处 《中国中药杂志》 CAS CSCD 北大核心 2013年第13期2109-2113,共5页 China Journal of Chinese Materia Medica
关键词 3-羧丙基-三苯基溴化鏻 聚乙二醇-聚己内酯 胶束 姜黄素 细胞毒性 CTPP PEG-PCL micelle curcumin cytotoxicity
  • 相关文献

参考文献16

  • 1Aggarwal B B, Kumar A, Bharti A C. Anticancer potential of curcumin preclinical and clinical studies [ J ]. Anticancer Res, 2003(33) :363.
  • 2Maheshwari R K, Singh A K, Gaddipati J, et al. Multiple biological activities of curcumin : a short review [ J ]. Life Sci, 2006, 78(18) :2081.
  • 3Huang M T. Phenolic compound in food and their effect on health Ⅱ[M]. Washington DC :American Chemical Society, 1992:34.
  • 4Saja K, Mani S B, Karunagaran D. Anti-inflammatory effect of curcumin involves down regulation of MMP-9 in blood mononuclear cells[ J]. Int hnmunopharmacol, 2007, 7 ( 13 ) : 1659.
  • 5Yallapu M M, Jaggi M, Chauhan S C, et al. Curcumin nanoformulations:a future nanomedicine for cancer [ J ]. Drug Discov Today, 2012, 17(1/2) :71.
  • 6Wang M E, Chen Y C, Chen S, et al. Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes [J]. J Nutr Biochem,2012, 23(10) :1352.
  • 7Ravind R V, Chandrasek H N. Absorption and tissue distribution of curcum in rats[J]. Toxicology, 1980, 16(3) :259.
  • 8Salmaso S, Bersani S, Semenzato A, et al. New cyclodextrin bioconjugates for active tumour targeting [ J ]. J Drug Target, 2007, 15(6) :379.
  • 9Marczylo T H, Verschoyle R D, Cooke D N, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine[ J ]. Cancer Chemother Pharmacol, 2007, 60(2) :171.
  • 10Murphy M P, Smith R A J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations[J]. Annu Rev Pharmacol Toxicol, 2007(47) :629.

同被引文献152

引证文献8

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部